Trial Profile
Randomized non-inferiority study comparing a strategy maintaining current enfuvirtide-based antiretroviral therapy to a strategy replacing enfuvirtide by an integrase inhibitor (raltegravir) in HIV-1 infected subjects with plasma HIV-1 RNA levels below 400 copies per ml
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Antiretrovirals; Enfuvirtide
- Indications HIV-1 infections
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms EASIER
- 24 Jun 2013 Results of a biomarker analysis published in the Journal of Infectious Diseases.
- 08 Mar 2012 Results reporting the effects of treatment on levels of inflammatory and coagulation biomarkers presented at the 19th Conference on Retroviruses and Opportunistic Infections.
- 01 Sep 2010 Health-related QOL results have been published in HIV Clinical Trials.